

1621 #6
RECEIVEDU.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

JUL 17 2002

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**Docket Number:
1662/54903**TECH CENTER 1600/2900**Application Number
10/000,428Filing Date
November 30, 2001Examiner
To be AssignedArt Unit
1621Invention Title
CRYSTALLINE VENLAFAXINE BASE AND NOVEL
POLYMORPHS OF VENLAFAXINE HYDROCHLORIDE,
PROCESSES FOR PREPARING THEREOFInventor(s)
Ben-Zion DOLITZKY et al.

Address to:


Commissioner for Patents
Washington D.C. 20231COPY OF PAPERS
ORIGINALLY FILEDI hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C. 20231
on

Date: 7/9/02 Reg. No. 46877


Signature: 

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the reference listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.

Dated: 7/9/02

By: 
Siu K. Lo (Reg. No. 46,877)KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 01662/54903	SERIAL NO. 10/000,428
	APPLICANT DOLITZKY et al.	
	FILING DATE November 30, 2001	GROUP 1621



U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB- CLASS	FILING DATE*

* - if pertinent

RECEIVED

JUL 17 2002

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE; PERTINENT PAGES, ETC.
		Daniel Vega et al. , 1-[2-(1-Hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl]dimethyl-ammonium chloride (venlafaxine hydrochloride), Acta Crystallographica Section C Crystal Structure Communications, 2000, C56, pp. 1009-1010

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**COPY OF PAPERS
ORIGINALLY FILED**